<PAGE>   1

                UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549
                                  FORM 10-QSB

[X] QUARTERLY REPORT UNDER SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934

                    FOR THE QUARTER ENDED SEPTEMBER 30, 1998

                                       OR

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT

              For the transition period from          to 
                                             --------    ---------


                         COMMISSION FILE NUMBER 1-14004

                                XENOMETRIX, INC.
        (Exact name of small business issuer as specified in its charter)

               DELAWARE                               04-3166089
    (State or other jurisdiction of                 (IRS employer
    incorporation or organization)              identification number)


                            2425 NORTH 55TH STREET
                               BOULDER, CO 80301
                    (Address of principal executive offices)


                                 (303) 447-1773
                           (Issuers telephone number)


   Check whether issuer (1) filed all reports required to be filed by Section 13
or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.

                                    Yes X    No
                                       ---     ---
   State the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date.

 COMMON STOCK, $0.001 PAR VALUE                        2,948,135 COMMON SHARES
          (Class)                              OUTSTANDING AT NOVEMBER 6, 1998


            Transitional Small Business Disclosure Format Yes     No X
                                                             ---    ---
<PAGE>   2
                                 XENOMETRIX, INC
                                   FORM 10-QSB
                     FOR THE PERIOD ENDED SEPTEMBER 30, 1998

                                      INDEX


PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements

<TABLE>
<S>                                                                           <C> 
      Balance Sheet - September 30, 1998......................................Page 3

      Statement of Operations - Quarters ended September 30, 1998 and 1997....Page 4

      Statement of Cash Flows - Quarters ended September 30, 1998 and 1997....Page 5

      Notes to Financial Statements...........................................Page 6

Item 2.  Management's Discussion and Analysis of Financial Condition and
         Results of Operations................................................Page 8



PART II - OTHER INFORMATION


Item 6.  Exhibits and Reports on Form 8-K.....................................Page 13

Signatures....................................................................Page 14
</TABLE>



                                       2
<PAGE>   3
Part One--Financial Information

                                XENOMETRIX, INC.
                                  Balance Sheet
                               September 30, 1998
                                   (Unaudited)

                                     Assets


<TABLE>
<S>                                                                  <C>         
Cash                                                                 $    100,000
Accounts receivable, net                                                  227,000
Inventory                                                                 153,000
Prepaid insurance                                                         116,000
Other current assets                                                       40,000
                                                                     ------------
       Total current assets                                               636,000

Property and equipment, net                                               600,000
Patents, net                                                              467,000
                                                                     ------------
                                                                     $  1,703,000
                                                                     ============

                      Liabilities and Stockholders' Equity

Accounts payable                                                     $    566,000
Accrued interest payable                                                  165,000
Accrued salaries and wages                                                220,000
Other accrued liabilities                                                 292,000
Senior promissory notes, net of discount                                1,478,000
                                                                     ------------
       Total current liabilities                                        2,721,000
                                                                     ------------

Stockholders' Equity:
Preferred stock--$.001 par value; 5,000,000 shares authorized;
    no shares issued and outstanding                                           --
Common stock--$.001 par value; 20,000,000 shares authorized;
    2,948,000 shares issued and outstanding                                 3,000
Additional paid-in capital                                             16,093,000
Accumulated deficit                                                   (17,114,000)
                                                                     ------------
       Total stockholders' equity                                      (1,018,000)
                                                                     ------------
                                                                     $  1,703,000
                                                                     ============
</TABLE>



The accompanying notes are an integral part of these financial statements.





                                       3
<PAGE>   4
                                XENOMETRIX, INC.
                             Statement of Operations
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                   Quarter Ended
                                                   September 30,
                                          ------------------------------
                                             1998               1997  
                                          -----------       ------------
<S>                                       <C>                <C> 
Revenue:
     Products and services                $    33,000        $   199,000
     Licensing revenue                        300,000                 --
                                          -----------        -----------
     Total revenue                            333,000            199,000
Cost of revenue:
     Cost of products and services             38,000            145,000
     Cost of licensing revenue                 68,000                 --
                                          -----------        -----------
     Total cost of revenue                    106,000            145,000
                                          -----------        -----------
        Gross profit                          227,000             54,000
                                          -----------        -----------
Research and development                      117,000            373,000
Selling, general and administrative           395,000            465,000
                                          -----------        -----------
     Total operating expense                  512,000            838,000
                                          -----------        -----------
Operating loss                               (285,000)          (784,000)
     Interest expense, net                   (131,000)          (110,000)
                                          -----------        -----------
Net loss                                  $  (416,000)       $  (894,000)
                                          ===========        ===========

Loss per common share-basic               $     (0.14)       $     (0.30)
                                          ===========        ===========


Weighted average shares outstanding         2,948,000          2,947,000
                                          ===========        ===========
</TABLE>





   The accompanying notes are an integral part of these financial statements.




                                       4
<PAGE>   5
                                XENOMETRIX, INC.
                             Statement of Cash Flows
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                        Quarter Ended
                                                                        September 30,
                                                                   -------------------------
                                                                     1998              1997
                                                                   ---------        ---------
<S>                                                                <C>              <C> 
Cash Flows from Operating Activities:
     Net loss                                                      $(416,000)       $(894,000)
     Adjustments to reconcile net loss to net cash
     used in operating activities:
          Depreciation and amortization                               91,000           88,000
          Amortization of note discount                               83,000           82,000
          Provision for doubtful accounts                             (5,000)              --
          Changes in assets and liabilities:
              Accounts receivable                                   (107,000)          93,000
              Receivable from termination of operating lease              --          115,000
              Inventory                                              (98,000)          (7,000)
              Prepaid insurance                                       65,000           49,000
              Other current assets                                    12,000          (44,000)
              Accounts payable and accrued liabilities               298,000           26,000
                                                                   ---------        ---------
          Net cash used in operating activities                      (77,000)        (492,000)
                                                                   ---------        ---------

Cash Flows from Investing Activities:
     Capital expenditures                                                 --           (2,000)
     Patent acquisition cost                                        (164,000)          (8,000)
                                                                   ---------        ---------
          Net cash used in investing activities                     (164,000)         (10,000)
                                                                   ---------        ---------

Net decrease in cash                                                (241,000)        (502,000)

Cash and cash equivalents at beginning of period                     341,000          603,000
                                                                   ---------        ---------

Cash and cash equivalents at end of period                         $ 100,000        $ 101,000
                                                                   =========        =========
</TABLE>




   The accompanying notes are an integral part of these financial statements.



                                       5
<PAGE>   6
                                XENOMETRIX, INC.
                          NOTES TO FINANCIAL STATEMENTS
                    FOR THE PERIOD ENDING SEPTEMBER 30, 1998
                                   (Unaudited)


1. Basis of Presentation

The accompanying financial statements are unaudited. However, in the opinion of
management, the accompanying financial statements reflect all adjustments,
consisting of only normal recurring adjustments, necessary for fair
presentation. Interim results of operations are not necessarily indicative of
results for the full year. These financial statements should be read in
conjunction with the Xenometrix Annual Report on Form 10-KSB for the year ended
June 30, 1998.

Except for the historical information contained in this Form 10-QSB, this Form
contains forward-looking statements that involve risks and uncertainties.
Xenometrix's actual results could differ materially from those discussed in this
Report. Factors that could cause or contribute to such differences include, but
are not limited to, those discussed in this Report and any documents
incorporated herein by reference, as well as in the Xenometrix Annual Report on
Form 10-KSB for the year ended June 30, 1998.

2.  Senior Promissory Notes

Between June 20, 1997 and January 12, 1998, Xenometrix issued Senior promissory
notes, (the "Notes") in the total amount of $1,500,000 to serve as bridge
financing. The Notes are collateralized by a security interest in all of the
assets of the Company. The Notes were originally due March 25, 1998. The
maturity date on the Notes has been extended several times, most recently until
February 25, 1999, (see Note 5). The Notes bear interest at 12% per annum. In
the event of a sale of the Company prior to the maturity date, the Notes are due
at the closing of such sale. In connection with the issuance of these Notes,
Xenometrix issued warrants to purchase 499,995 shares of common stock. In
consideration for the extension of the due date on the Notes to February 25,
1999, the exercise price of the warrants was reduced to $0.125 per share and the
Company agreed to continue to pay 38.5% of all gross licensing revenues received
during the extension period to the Note holders, as payment against the accrued
interest and principal due on the Notes. In the event of default by the Company
on the Notes, the interest rate will increase to 18% per annum, the Note holders
will have the right to appoint a majority of the Board of Directors of the
Company and the Company's assets will be subject to foreclosure.

3.  Earnings (Loss) Per Common Share

Effective for the quarter ended September 30, 1998, net loss per common share is
computed using the Financial Accounting Standards Board's Statement of Financial
Accounting Standards (SFAS) No. 128, "Earnings Per Share" (EPS). SFAS No. 128
establishes new standards for computing and presenting EPS and supercedes all
prior EPS guidance found in APB 




                                       6
<PAGE>   7
Opinion 15. EPS for all prior periods has been restated to conform with the
requirements of SFAS No. 128.

Basic loss per common share is computed by dividing the net loss by the
weighted-average number of common shares outstanding during the period.

Diluted loss per share is computed using the treasury stock method, based upon
the weighted-average number of common shares, dilutive common stock equivalent
shares and the assumed conversion of any dilutive convertible securities
outstanding during the period. Because the inclusion of these common stock
equivalents and convertible securities would be anti-dilutive, they are excluded
from the Company's calculation of diluted loss per share.

4.    Recently Issued Accounting Standards

In June 1997, the FASB issued SFAS No. 131, "Disclosures about Segments of an
Enterprise and Related Information." SFAS No. 131, which is effective for fiscal
years beginning after December 15, 1997, establishes new disclosure requirements
for operating segments, including products, services, geographic areas, and
major customers. The Company has adopted SFAS No. 131 for the 1999 fiscal year,
but does not expect the new accounting standard to have a material effect on the
Company's reported financial results.

5.    Subsequent Events

On October 12, 1998, Xenometrix entered into a license agreement with Gene
Logic, Inc. ("Gene Logic") granting Gene Logic a non-exclusive license to the
gene expression profiling claims contained in issued U. S. and European patents.
The license incorporates up-front fees and a potential royalty stream for
Xenometrix, as well as potential future research collaborations between the
parties.

On October 25, 1998, Xenometrix entered into an agreement with the holders of
the Notes extending the maturity date of the Notes to February 25, 1999 from
October 25, 1998. In consideration for this extension, the exercise price of the
499,995 warrants previously issued to the Note holders was reduced to $0.125 per
share from $0.37 per share. The interest rate on the Notes remains at 12% per
annum and Xenometrix will continue to pay 38.5% of all gross licensing revenues
received during the extension period to the Note holders as payment against the
outstanding interest and principal due on the Notes. In the event of a sale of
the Company prior to February 25, 1999, the Notes will be due at the closing of
such sale.



                                       7
<PAGE>   8
ITEM 2.                         XENOMETRIX, INC.
                     MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS

   The following discussion of the results of operations and financial condition
should be read in conjunction with the financial statements and notes thereto
appearing elsewhere in this Report. Except for the historical information
contained herein, this Report contains forward-looking statements that involve
risks and uncertainties. Xenometrix's actual results could differ materially
from those discussed in this Report. Factors that could cause or contribute to
such differences include, but are not limited to, those discussed in this Report
and any documents incorporated herein by reference, as well as in the Xenometrix
Annual Report on Form 10-KSB for the fiscal year ended June 30, 1998.

OVERVIEW

   Initially, the Company's efforts were focused upon commercializing its
technology in the field of molecular toxicology. Accordingly, the Company's
resources were directed primarily at the product safety and toxicology markets.
In early 1997, the Company concluded that its proprietary gene profiling
technology may provide valuable information that could be used by pharmaceutical
researchers to optimize drug leads. While the Company has continued to serve the
drug safety and toxicology market, it has been focusing a significant portion of
its effort and resources developing and marketing its products and services to
pharmaceutical companies for testing, evaluation and optimization of their lead
compounds.

   Recently, the Company has put considerable effort into the licensing of its
intellectual property. On January 22, 1998, the Company announced that it had
been granted a broad basic patent by the European Patent Office covering most
gene expression profiles resulting from the exposure of eukaryotic cells
(including human, animal and yeast cells) to pharmaceutical compounds and other
chemical entities. On September 22, 1998, the United States Patent and Trademark
Office issued a patent to the Company covering similar claims in the United
States. The Company plans to aggressively pursue licensing of these patents and
entering into broader business collaborations with parties whose current or
future business activities may be covered by the claims contained in these two
patents.

   The timing and amount of revenues from sales of products and services to the
drug discovery and development market and to the toxicology and product safety
markets cannot be predicted with certainty. Similarly, the Company's ability to
enter into license agreements and meaningful collaborative arrangements with
customers or other potential collaborators and licensees cannot be predicted
with a high degree of accuracy. Accordingly, results of operations for any
period may be unrelated to results of operations for any other period and are
likely to fluctuate sharply. In addition, historical results should not be
viewed as indicative of future operating results.


                                       8
<PAGE>   9
   As of November 5, 1998 the Company had cash of approximately $100,000. The
Company estimates that its current resources together with projected collections
on accounts receivable from customers will be sufficient to meet its operating
needs through approximately December 1, 1998. Xenometrix is currently in
discussions with several companies regarding licensing of the Company's U. S.
and European gene profiling patents, and is hopeful that additional revenue from
these licenses will be sufficient to fund the Company's operating needs for the
next few months.

   The Company has royalty obligations to Harvard University which are currently
past due. The Company also has $1,500,000 of bridge notes which are due on
February 25, 1999, subject to further extension. The Company believes that it is
unlikely that it can generate sufficient licensing revenue to fund the Company's
operations, pay the amounts due to Harvard and pay off the Notes on the maturity
date. Accordingly, it is seeking strategic partnerships that may satisfy all of
these needs, including but not limited to, the sale of the Company. In the event
the Company cannot raise additional capital or does not generate sufficient
licensing revenue to fund operations, pay the amounts due to Harvard and repay
the Notes on the maturity date, it will seek to secure a further extension of
the maturity date of the notes. In addition, the Company will evaluate other
options including, but not limited to, further curtailing or suspending its
operations. (See Liquidity and Capital Resources).



RESULTS OF OPERATIONS

COMPARISON OF QUARTERS ENDED SEPTEMBER 30, 1998 AND 1997

   Revenue. For the quarter ended September 30, 1998, revenue increased 67% to
$333,000 from $199,000 reported in the comparable quarter of the prior year. The
increase was attributable to revenue from up-front licensing fees relating to
the Company's recently issued gene expression profiling patents in the United
States and Europe. Sales of products and service revenue from the Company's
client research laboratory declined 83% to $33,000, from $199,000 reported in
the prior year, due to a decline in the demand for assay kits and a reduction in
the level of completed laboratory service work. During the current quarter,
however, the Company completed a substantial portion of the work on a client
research laboratory contract for a major international pharmaceutical company
that is evaluating the Company's technology. In accordance with the Company's
past practices, the revenue and costs associated with performing this work will
be recognized in the quarter in which the work is completed.

   Gross Profit. For the quarter ended September 30, 1998, gross profit
increased to $227,000 from $54,000 reported in the prior year. The increase in
gross profit was due to the large portion of total revenue from licensing fees
and option payments. The cost of licensing revenue was $68,000, representing
royalties due to Harvard University under the Company's existing licensing
agreement and a portion of the amortization of the costs associated with the
patents. Gross profit margins on revenue from sales of products and services
were -15% in 

                                       9
<PAGE>   10
the current fiscal year, primarily due to fixed manufacturing costs being spread
over a relatively low revenue base.

   Research and Development Expenses (R&D). R&D expenses for the quarter ended
September 30, 1998 decreased 69% to $117,000 from $373,000 reported in the same
quarter of the prior year. This decrease was primarily attributable to reduced
headcount in the R&D department and personnel costs in the R&D department being
allocated to the cost of products and services sold and allocated to deferred
costs associated with client research laboratory work in progress. Laboratory
supplies expense and most other expenses in the R&D department were also down in
the current quarter, compared to the comparable quarter of the prior year. Also,
in the quarter ended September 30, 1997, personnel costs from other departments
were allocated to the R&D department, as scientists from these areas assisted
with research and product development projects.

   Selling, General and Administrative Expenses (SG&A). For the quarter ended
September 30, 1998, SG&A expenses were $395,000, down 15% from $465,000 in the
prior year. This decrease was primarily attributable to lower business
development, legal, finance, accounting and administrative costs resulting from
personnel reductions in February 1998 and lower Board of Directors costs
associated with reducing the size of the Board and replacing cash compensation
to Board members with increased stock option grants. These cost savings were
partially offset by higher costs for directors and officers liability insurance.

   Interest Expense, Net. During the quarter ended September 30, 1998, the
Company incurred net interest expense of $131,000 compared to $110,000 in the
comparable quarter of the prior fiscal year. The increase in net interest
expense in the current quarter is primarily due to the higher average balance
due on the Notes in the current quarter. The net interest expense incurred in
the both quarters includes interest accrued on the Notes at the stated interest
rate and the amortization of the values attributable to the warrants issued in
conjunction with the Notes.

   Net Loss. For the quarter ended September 30, 1998, the net loss decreased to
$416,000 or $0.14 per share from the net loss of $894,000 or $0.30 per share,
reported for the comparable quarter of 1997.

IMPACT OF YEAR 2000 ISSUES

   The Year 2000 issue is related to computer software utilizing two digits
rather than four to define the appropriate year. As a result, any of the
Company's computer programs or any of the Company's suppliers or vendors that
have date sensitive software may incur system failures or generate incorrect
data if "00" is recognized as 1900 rather than 2000.

   The Company has evaluated the proprietary software used to facilitate
performing, analyzing and interpreting the results of its assays, and the
proprietary software used in conjunction with its bioinformatics data base, and
found them to appropriately address the date issues associated with the year
2000. The Company believes that all dates in its proprietary software are 


                                       10
<PAGE>   11
stored with either a minimum of four digits for the year or as a text string,
thereby preventing inappropriate sequencing of date sensitive information. While
the Company believes that its proprietary software will not produce any material
problems, erroneous calculations or degradation of performance as a result of
Year 2000 issues, users are advised that the Company's software must be run on
Year 2000 compliant platforms.

   The Company plans to verify whether its major suppliers, service providers
and financial institutions are Year 2000 compliant, however there can be no
assurance that the systems and networks of its key suppliers and customers will
not be affected by Year 2000 issues, which could have an adverse effect on the
Company's business, operating results and financial condition. The Company
believes, based upon the evaluations performed upon its proprietary software and
the claims of Year 2000 compliance made by the providers of non-proprietary
software used by the Company, that the impact of Year 2000 will not be material.
However, to the extent the Company or third parties upon which it relies do not
timely achieve Year 2000 readiness, the Company's results of operations may be
adversely affected.

LIQUIDITY AND CAPITAL RESOURCES

   At September 30, 1998, the Company had cash of $100,000. During the three
month period ended September 30, 1998, $77,000 was used to fund Xenometrix'
operations, $164,000 was invested in patents, and there were no cash resources
generated from or used for financing activities.

   As of November 5, 1998, the Company had cash of approximately $100,000
compared with $341,000 at June 30, 1998. The Company estimates that its current
resources together with projected collections on accounts receivable from
customers will be sufficient to meet its operating needs through approximately
December 1, 1998. Xenometrix is currently in discussions with several companies
regarding licensing of the Company's U. S. and European gene profiling patents,
and is hopeful that additional revenue from these licenses will be sufficient to
fund the Company's operating needs for the next few months.

   In order to fund its operations, the Company has borrowed $1,500,000 under a
short-term bridge financing line of credit. The due date on the Notes issued
under the line of credit has been extended several times, most recently until
February 25, 1999. In consideration for the extension, Xenometrix agreed to
reduce the exercise price of the 499,995 warrants (the "Warrants") issued in
conjunction with the Notes to $0.125 per share and agreed to continue to pay to
the Note holders a total of 38.5% of all gross licensing revenues received
during the extension period. These payments will be applied first to the accrued
interest payable on the Notes and then applied to reduce the principal balance
due on the Notes. In conjunction with the extension, the Note holders agreed to
maintain the interest rate on the Notes at 12% and further agreed that in the
event that the Company is acquired by a third party at a price per share that is
greater than the exercise price of the Warrants, to surrender the Warrants at
the closing of such acquisition in exchange for either cash or freely tradable
common stock of the acquiring company in an aggregate amount equal to the
difference between the acquisition price per share and the exercise price per



                                       11
<PAGE>   12
share of the warrants, multiplied by the total number of Warrants held by the
Note holders.

   The Company's principal patents relate to gene expression profiling.
Xenometrix shares ownership of these patents with Harvard University ("Harvard")
and has an exclusive world-wide license (the "Agreement") to Harvard's portion
of the intellectual property. At June 30, 1998, the Company determined that it
owed Harvard approximately $108,000 under the Agreement, which was due and
payable on August 29, 1998. Failure to make payments when due constitutes an
event of default under the Agreement. On September 30, 1998, the Company
received written notice of default from Harvard. The Company's continued failure
to make such payment within ninety days after receipt by the Company of a
written notice of such event of default from Harvard, is grounds for termination
of the Agreement by Harvard. As of November 5, 1998, this amount had not been
paid, due to the Company's lack of available funds. In the event that this
payment is not made within the timeframe outlined above, the Company could lose
its license to Harvard's ownership interest in the patents which would have a
material adverse effect on the Company's business, financial condition and
results of operations.

   The Company believes that it is unlikely that it can generate sufficient
licensing revenue to fund the Company's operations, pay the amounts due to
Harvard and pay off the Notes on the maturity date. Accordingly, it is seeking
strategic partnerships that may satisfy all of these needs, including but not
limited to, the sale of the Company. In the event the Company cannot raise
additional capital or does not generate sufficient licensing revenue to fund
operations, pay the amounts due to Harvard and repay the notes it will seek to
secure a further extension of the maturity date of the notes. In addition, the
Company will evaluate other options including, but not limited to, further
curtailing or suspending its operations.




                                       12
<PAGE>   13
                           PART II--OTHER INFORMATION


ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K.


(a)  Exhibits

      10.44* License agreement dated September 30, 1998 between Affymetrix, Inc.
      and the Registrant.

      10.45* License agreement dated October 12, 1998 between Gene Logic, Inc.
      and the Registrant.

      10.46 Amendment to the Senior Line of Credit Agreement and Notes, dated as
      of October 25, 1998 by and among The Aries Domestic Fund, L.P., The Aries
      Fund, a Cayman Island Trust and the Registrant.

      10.47 Form of warrant issued to The Aries Domestic Fund, L.P. and The
      Aries Fund, a Cayman Island Trust.

      27.1 Summary Financial Information Schedule


(b)  Reports on Form 8-K

       No Form 8-K reports were filed during the period covered by this Report.

      ----------------

      * Xenometrix is applying for confidential treatment with respect to
        portions of this exhibit.




                                       13
<PAGE>   14
                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company
has duly caused this Report to be signed on its behalf.

                                XENOMETRIX, INC.



                        /s/ Stephen J. Sullivan

November 13, 1998       Stephen J. Sullivan
                        President, Chief Executive Officer
                        And Director




                        /s/ Ronald L. Hendrick

November 13, 1998       Ronald L. Hendrick
                        Executive Vice President and Chief Financial Officer
                        Principal Accounting and Financial Officer



                                       14
<PAGE>   15
                                  EXHIBIT INDEX


Exhibit No.                             Description

10.44*      License agreement dated September 30, 1998 between Affymetrix, Inc.
            and the Registrant.

10.45*      License agreement dated October 12, 1998 between Gene Logic, Inc.
            and the Registrant.

10.46       Amendment to the Senior Line of Credit Agreement and Notes, dated as
            of October 25, 1998 by and among The Aries Domestic Fund, L.P., The
            Aries Fund, a Cayman Island Trust and the Registrant.

10.47       Form of warrant issued to The Aries Domestic Fund, L.P. and The
            Aries Fund, a Cayman Island Trust.

27.1        Summary Financial Information Schedule


*           Xenometrix is applying for confidential treatment with respect to
            portions of this exhibit.


                                       15